What if the next frontier in anti-ageing skincare was not about encouraging the skin to produce more collagen, smoothing fine lines or restoring lost volume, but targeting the ageing cells themselves?
This month, WIRED reported on preliminary results from Rubedo Life Sciences, a biotechnology company investigating a topical drug intended to target damaged cells that have stopped dividing but remain active in the skin. The findings are intriguing, but the research is still at an early stage. They do not yet demonstrate that the treatment can reliably reverse visible ageing in healthy skin.
Nevertheless, the science behind the research could mean that in the future, treatments might possibly address some of the cellular processes underlying skin ageing, rather than concentrating primarily on its visible signs.
So what are ‘zombie cells’? The term ‘zombie cells’ is a popular description of senescent cells. These are cells that have stopped dividing, often in response to DNA damage, oxidative stress or other cellular threats, but have not been cleared from the body.
Cellular senescence is not inherently harmful. It is part of the body’s protective response to damaged cells and plays a role in wound healing and tumour suppression. By preventing potentially dangerous cells from continuing to divide, senescence can help limit the development of cancer.
Problems can arise, however, when senescent cells accumulate in tissues. Although they no longer divide, they remain metabolically active and can release inflammatory molecules, enzymes and other substances that affect neighbouring cells.
This collection of secretions is known as the senescence-associated secretory phenotype, or SASP. Over time, it may contribute to chronic inflammation, tissue dysfunction and the breakdown of the extracellular matrix, which provides structural support to the skin.
In ageing skin, these processes are particularly relevant.
However, senescence is only one part of a complex picture. Hormonal changes, genetics, environmental exposure, inflammation and alterations in skin-barrier function also influence how skin ages.
The Experimental Cream Attracting Attention
Rubedo Life Sciences is investigating a drug designed to target a survival mechanism used by certain senescent cells. According to WIRED’s recent report, the topical treatment works by briefly inhibiting a protein called GPX4, with the aim of triggering the death of targeted cells.
The approach falls within the field of senolytics: treatments designed to selectively eliminate senescent cells. Related strategies, known as senomorphics, aim to modify the harmful behaviour of these cells without necessarily removing them.
The distinction matters. Eliminating a problematic cell and reducing the inflammatory substances it releases are different biological objectives, and they may require different treatments.
The company reported early findings from a small clinical trial involving 11 people with atopic dermatitis, an inflammatory skin condition. After four weeks of treatment, an independent analysis of skin samples suggested that participants’ biological skin age had decreased by an average of approximately two years. One participant recorded a reduction of more than 11 years.
The analysis was conducted by Mitra Bio using an epigenetic ageing clock based on DNA methylation patterns. Such clocks estimate biological ageing from molecular markers; they do not directly measure how old a person looks or establish that wrinkles have disappeared.
The report also described changes in inflammatory markers and collagen-related measures. Separately, a study involving 18 people reportedly found a 46% reduction in lesions associated with sun damage.
These results offer a reason for further investigation, not proof of a new anti-ageing breakthrough.
The participant groups were very small, follow-up was limited, and the reported findings do not establish how the treatment performs in larger populations or in people seeking cosmetic rejuvenation rather than treatment for a skin condition.
Could Targeting Senescent Cells Improve Skin Quality?
The potential appeal for aesthetic medicine lies in the possibility of addressing biological processes which contribute to visible ageing.
Many established aesthetic treatments work by stimulating collagen production, improving the skin’s surface, reducing pigmentation or restoring volume. Retinoids, selected laser treatments, microneedling and certain energy-based procedures can influence skin renewal or collagen remodelling, although their mechanisms and evidence vary.
A treatment which safely modifies senescence could, in theory, complement these approaches by influencing inflammation, tissue repair and the environment in which collagen-producing cells operate.
There is some supporting research beyond the latest news. A 2024 study published in Aging investigated topical ABT-263 in aged mice. Researchers found reductions in several markers of cellular senescence and faster wound closure after treatment. However, the treatment also caused a temporary inflammatory response, and results in animals cannot establish that the same effects will occur in human skin.
Other exploratory research has examined topical rapamycin and platelet-derived preparations in human skin, investigating changes in senescence-related markers and tissue structure.
These are different interventions, however, and their findings should not be treated as evidence that all approaches targeting cellular ageing will deliver the same results.
For aesthetic practitioners, the central question is whether measurable molecular changes translate into improvements patients can actually see and feel. The future remains to be unveiled.
